Form 4: Alaunos Therapeutics Director Acquires Convertible Preferred Stock

Alaunos Therapeutics Director Jaime Vieser reported the acquisition of 250 shares of Series A-2 Convertible Preferred Stock, signaling insider confidence.

Summary

• Jaime Vieser, a Director of Alaunos Therapeutics, Inc. (TCRT), reported a change in beneficial ownership.
• The transaction involved the acquisition of 250 shares of Series A-2 Convertible Preferred Stock.
• The transaction date was June 24, 2025.
• Each share of Series A-2 Convertible Preferred Stock has a conversion price of $4.49 and is convertible into 55,679.29 shares of common stock.
• Following this reported transaction, Jaime Vieser directly beneficially owns 250 shares of Series A-2 Convertible Preferred Stock.
• The preferred stock is perpetual and does not have an expiration date.

Sentiment

Score: 7

Explanation: The acquisition of convertible preferred stock by a director is generally viewed positively as it indicates insider confidence in the company's future, though it's a single transaction.

Positives

• A director, Jaime Vieser, purchased 250 shares of Series A-2 Convertible Preferred Stock, which can be interpreted as a positive signal of insider confidence in the company's future prospects.

Related Party Transactions

• Acquisition of 250 shares of Series A-2 Convertible Preferred Stock by Director Jaime Vieser from Alaunos Therapeutics, Inc.

Stakeholder Impact

• Shareholders may view this insider acquisition as a positive indicator of management's belief in the company's value and future performance.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Form 4, Insider Transaction, Beneficial Ownership, Preferred Stock, Director Acquisition, Convertible Securities